Immune thrombocytopenia - Pipeline Insight, 2021
This report can be delivered to the clients within 72 hours
DelveInsight’s, “Immune thrombocytopenia - Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Immune thrombocytopenia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Immune thrombocytopenia: Overview
Immune thrombocytopenia (ITP), formerly known as Idiopathic thrombocytopenic purpura is an autoimmune bleeding disorder. The disease is characterized by abnormally low levels of blood cells called platelets. ITP manifests as a bleeding tendency, easy bruising (purpura), or extravasation of blood from capillaries into skin and mucous membranes (petechiae). The diagnosis of ITP is made by excluding other causes of thrombocytopenia along with blood tests. Treatment for ITP is based on goals to prevent bleeding and stabilize as well as improvement in platelet count. Corticosteroid drugs like prednisone, dexamethasone, and methylprednisolone is usually the mainstay of first line therapy. In 2008, the FDA approved Nplate and Promacta to treat both children and adults with ITP who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.
'Immune thrombocytopenia - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Immune thrombocytopenia pipeline landscape is provided which includes the disease overview and Immune thrombocytopenia treatment guidelines. The assessment part of the report embraces, in depth Immune thrombocytopenia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Immune thrombocytopenia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Immune thrombocytopenia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Immune thrombocytopenia Emerging Drugs
Further product details are provided in the report……..
Immune thrombocytopenia: Therapeutic Assessment
This segment of the report provides insights about the different Immune thrombocytopenia drugs segregated based on following parameters that define the scope of the report, such as:
Immune thrombocytopenia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Immune thrombocytopenia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Immune thrombocytopenia drugs.
Immune thrombocytopenia Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Immune thrombocytopenia - Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Immune thrombocytopenia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Immune thrombocytopenia: Overview
Immune thrombocytopenia (ITP), formerly known as Idiopathic thrombocytopenic purpura is an autoimmune bleeding disorder. The disease is characterized by abnormally low levels of blood cells called platelets. ITP manifests as a bleeding tendency, easy bruising (purpura), or extravasation of blood from capillaries into skin and mucous membranes (petechiae). The diagnosis of ITP is made by excluding other causes of thrombocytopenia along with blood tests. Treatment for ITP is based on goals to prevent bleeding and stabilize as well as improvement in platelet count. Corticosteroid drugs like prednisone, dexamethasone, and methylprednisolone is usually the mainstay of first line therapy. In 2008, the FDA approved Nplate and Promacta to treat both children and adults with ITP who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.
'Immune thrombocytopenia - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Immune thrombocytopenia pipeline landscape is provided which includes the disease overview and Immune thrombocytopenia treatment guidelines. The assessment part of the report embraces, in depth Immune thrombocytopenia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Immune thrombocytopenia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Immune thrombocytopenia R&D. The therapies under development are focused on novel approaches to treat/improve Immune thrombocytopenia.
This segment of the Immune thrombocytopenia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Immune thrombocytopenia Emerging Drugs
- Rozanolixizumab (UCB7665): UCB
- Efgartigimod: arGEN-X
Further product details are provided in the report……..
Immune thrombocytopenia: Therapeutic Assessment
This segment of the report provides insights about the different Immune thrombocytopenia drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Immune thrombocytopenia
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Immune thrombocytopenia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Immune thrombocytopenia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Immune thrombocytopenia drugs.
Immune thrombocytopenia Report Insights
- Immune thrombocytopenia Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Immune thrombocytopenia drugs?
- How many Immune thrombocytopenia drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Immune thrombocytopenia?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Immune thrombocytopenia therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Immune thrombocytopenia and their status?
- What are the key designations that have been granted to the emerging drugs?
- UCB
- arGEN-X
- HanAll Biopharma/Immunovant
- Bioverativ
- Momenta Pharmaceuticals
- Principia Biopharma
- Hutchison MediPharma
- Cour Pharmaceutical Development
- Rozanolixizumab (UCB7665)
- Efgartigimod
- Batoclimab
- BIVV-020
- M 254
- Rilzabrutinib
- Sutimlimab
- HMPL 523
- M 230
- CNP-105
Introduction
Executive Summary
Immune thrombocytopenia: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Immune thrombocytopenia – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Rozanolixizumab (UCB7665): UCB
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
BIVV-020: Bioverativ
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
M 254: Momenta Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical/Discovery Stage Products
Comparative Analysis
CNP-105: Cour Pharmaceutical Development
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Immune thrombocytopenia Key Companies
Immune thrombocytopenia Key Products
Immune thrombocytopenia- Unmet Needs
Immune thrombocytopenia- Market Drivers and Barriers
Immune thrombocytopenia- Future Perspectives and Conclusion
Immune thrombocytopenia Analyst Views
Appendix
Executive Summary
Immune thrombocytopenia: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Immune thrombocytopenia – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Rozanolixizumab (UCB7665): UCB
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
BIVV-020: Bioverativ
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
M 254: Momenta Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical/Discovery Stage Products
Comparative Analysis
CNP-105: Cour Pharmaceutical Development
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Immune thrombocytopenia Key Companies
Immune thrombocytopenia Key Products
Immune thrombocytopenia- Unmet Needs
Immune thrombocytopenia- Market Drivers and Barriers
Immune thrombocytopenia- Future Perspectives and Conclusion
Immune thrombocytopenia Analyst Views
Appendix
LIST OF TABLES
Table 1 Total Products for Immune thrombocytopenia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Immune thrombocytopenia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Immune thrombocytopenia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Immune thrombocytopenia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products